EGFR and non-small cell lung carcinoma: It was found that the study conducted by Wu et al in 2014,[18] titled “Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harboring EGFR mutations (LUX-Lung 6): an open-label, randomized phase 3 trial,” published in The Lancet Oncology, demonstrated the most robust citation burst (2015–2019, strength 11.46).